Drug intelligence / Profile preview

RO7565020

Development stage: Phase 1
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

RO7565020 is a human origin monoclonal antibody developed for the treatment of chronic hepatitis B virus (HBV) infection. It works by attaching to the HBV and neutralizing it, potentially aiding the body's immune system in clearing the virus. The drug is administered via subcutaneous injection or intravenous infusion. It is currently under investigation in Phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and those with chronic hepatitis B infection. The development aims to provide an alternative or adjunctive therapy to nucleos(t)ide analogue treatments that are often lifelong[1][3][4].

Other names: RO-7565020RO7565020RO 7565020

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on RO7565020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO7565020.

Explore the full profile